|
1
|
Lieshout-Krikke R, Hoad V, Chua SS, Kam G, Satake M, Hino I, Stramer SL, Groves JA, de La Taille V, Laperche S, Cheng A, Goodison K, Tsoi WC, Lee CK, Prati D, Pati I, Drews SJ, Bigham M, Gratz G, Jungbauer C, Charlewood R, Smith M, O'Flaherty N, Raftery A, Oyonarte S, Gubbe K, Luhm J, Ngcobo S, Slot E, Davison K, Brailsford S, Dunbar N. International Forum on Donor- and Recipient-triggered Lookback for Traditional Transfusion-transmitted Infections: Summary. Vox Sang 2024. [PMID: 39542027 DOI: 10.1111/vox.13763] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2024] [Accepted: 10/15/2024] [Indexed: 11/17/2024]
|
|
3
|
Clerico M, Dogliotti I, Ghione P, Zilioli VR, Merli F, Botto B, Al Essa W, Battaglini M, Grimaldi D, Cervi L, Ragaini S, Ferrero S, Peri V, De Luca G, Marzano A, Cavallo F. HBV Reactivation in Patients with Past Infection Affected by Non-Hodgkin Lymphoma and Treated with Anti-CD20 Antibody Based Immuno-Chemotherapy: A Multicenter Experience. J Pers Med 2022; 12:jpm12020285. [PMID: 35207774 PMCID: PMC8875663 DOI: 10.3390/jpm12020285] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2021] [Revised: 02/07/2022] [Accepted: 02/11/2022] [Indexed: 11/16/2022] Open
Abstract
Hepatitis B virus reactivation (HBVr) can develop in HBV surface antigen (HBsAg) positive or HBsAg-negative and anti-hepatitis B core antigen antibodies (anti-HBc) positive (past HBV infection) patients receiving immuno-chemotherapy for hematological malignancies. A higher rate of HBVr is associated with the use of rituximab (R) in patients with past HBV infection, thus justifying an antiviral prophylaxis. In this study we evaluated the incidence of HBVr in a real-life cohort of 362 anti-HBc-positive subjects affected by non-Hodgkin lymphoma (NHL), mainly receiving lamivudine (LAM) prophylaxis (93%) and all undergoing a R-containing regimen. A retrospective, multicenter, observational study was conducted in 4 Italian Hematology Departments. The primary endpoint was the incidence of virologic (HBV DNA-positive), serologic (HBsAg-positive) and clinical (ALT increase > 3 × upper limit of normal) HBVr, which occurred in five, four and one patients, respectively, with a total HBVr rate of 1.4%. None of them had to discontinue the chemotherapy program, while two patients required a delay. Treatment-related adverse events (AEs) were reported during LAM prophylaxis in three patients (0.9%). In conclusion, this study confirms the efficacy and safety of LAM prophylaxis in anti-HBc-positive patients undergoing R-containing regimens.
Collapse
Affiliation(s)
- Michele Clerico
- Division of Hematology, Department of Molecular Biotechnology and Health Sciences, University of Torino, A.O.U. Città della Salute e della Scienza di Torino, 10126 Turin, Italy; (M.C.); (S.R.); (S.F.); (V.P.); (G.D.L.)
| | - Irene Dogliotti
- Stem Cell Transplant Unit, A.O.U. Città della Salute e della Scienza di Torino, 10126 Turin, Italy;
| | - Paola Ghione
- Lymphoma Program, Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA;
| | | | - Francesco Merli
- Division of Hematology, Azienda Unità Sanitaria Locale—IRCCS, 42123 Reggio Emilia, Italy;
| | - Barbara Botto
- Division of Hematology, A.O.U. Città della Salute e della Scienza di Torino, 10126 Turin, Italy;
| | - Wael Al Essa
- Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont, 28100 Novara, Italy;
| | - Marcella Battaglini
- DDINOGMI, Department University of Genoa, IRCCS Istituto Giannina Gaslini, 16147 Genoa, Italy;
| | - Daniele Grimaldi
- Division of Hematology, A.O.S. Croce e Carle, 12100 Cuneo, Italy;
| | - Loretta Cervi
- Division of Pharmacy, ASST Grande Ospedale Metropolitano Niguarda, 20162 Milan, Italy;
| | - Simone Ragaini
- Division of Hematology, Department of Molecular Biotechnology and Health Sciences, University of Torino, A.O.U. Città della Salute e della Scienza di Torino, 10126 Turin, Italy; (M.C.); (S.R.); (S.F.); (V.P.); (G.D.L.)
| | - Simone Ferrero
- Division of Hematology, Department of Molecular Biotechnology and Health Sciences, University of Torino, A.O.U. Città della Salute e della Scienza di Torino, 10126 Turin, Italy; (M.C.); (S.R.); (S.F.); (V.P.); (G.D.L.)
| | - Veronica Peri
- Division of Hematology, Department of Molecular Biotechnology and Health Sciences, University of Torino, A.O.U. Città della Salute e della Scienza di Torino, 10126 Turin, Italy; (M.C.); (S.R.); (S.F.); (V.P.); (G.D.L.)
| | - Gabriele De Luca
- Division of Hematology, Department of Molecular Biotechnology and Health Sciences, University of Torino, A.O.U. Città della Salute e della Scienza di Torino, 10126 Turin, Italy; (M.C.); (S.R.); (S.F.); (V.P.); (G.D.L.)
| | - Alfredo Marzano
- Division of Gastroenterology and Hepatology, San Giovanni Battista Hospital, 10126 Turin, Italy;
| | - Federica Cavallo
- Division of Hematology, Department of Molecular Biotechnology and Health Sciences, University of Torino, A.O.U. Città della Salute e della Scienza di Torino, 10126 Turin, Italy; (M.C.); (S.R.); (S.F.); (V.P.); (G.D.L.)
- Correspondence: ; Tel.: +39-011-633-4556; Fax: +39-011-633-6507
| |
Collapse
|